- Home
- GLMD vs MYNZ Comparison
GLMD vs MYNZ Comparison
Compare GLMD & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- MYNZ
- Stock Information
- Founded
- GLMD 2000
- MYNZ 2021
- Country
- GLMD Israel
- MYNZ Germany
- Employees
- GLMD N/A
- MYNZ N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- MYNZ Health Care
- Exchange
- GLMD Nasdaq
- MYNZ Nasdaq
- Market Cap
- GLMD 6.6M
- MYNZ 7.9M
- IPO Year
- GLMD 2014
- MYNZ 2021
- Fundamental
- Price
- GLMD $1.18
- MYNZ $1.37
- Analyst Decision
- GLMD Hold
- MYNZ Buy
- Analyst Count
- GLMD 1
- MYNZ 2
- Target Price
- GLMD N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- GLMD 65.7K
- MYNZ 181.8K
- Earning Date
- GLMD 11-14-2025
- MYNZ 12-29-2025
- Dividend Yield
- GLMD N/A
- MYNZ N/A
- EPS Growth
- GLMD N/A
- MYNZ N/A
- EPS
- GLMD N/A
- MYNZ N/A
- Revenue
- GLMD N/A
- MYNZ $659,935.00
- Revenue This Year
- GLMD N/A
- MYNZ N/A
- Revenue Next Year
- GLMD N/A
- MYNZ $5.03
- P/E Ratio
- GLMD N/A
- MYNZ N/A
- Revenue Growth
- GLMD N/A
- MYNZ N/A
- 52 Week Low
- GLMD $1.15
- MYNZ $1.21
- 52 Week High
- GLMD $3.61
- MYNZ $14.39
- Technical
- Relative Strength Index (RSI)
- GLMD 32.65
- MYNZ 40.67
- Support Level
- GLMD $1.16
- MYNZ $1.21
- Resistance Level
- GLMD $1.27
- MYNZ $1.47
- Average True Range (ATR)
- GLMD 0.08
- MYNZ 0.11
- MACD
- GLMD -0.02
- MYNZ -0.01
- Stochastic Oscillator
- GLMD 0.00
- MYNZ 33.41
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.